Abstracts tagged "autoimmune diseases"

Abstract Number: 0563 • ACR Convergence 2022
High-Dimensional Immunophenotyping with Mass Cytometry Reveals Unique Immune Cell Aberrations in Patients with Undiagnosed Inflammatory and Autoimmune Diseases
Alisa Mueller¹, Takanori Sasaki², Joshua Keegan¹, Jennifer Nguyen¹, Alec Griffith¹, Elizabeth Feig¹, Alice Horisberger³, Ye Cao¹, Gregory Keras¹, Lauren Briere⁴, Laurel Cobban¹, Daimon Simmons¹, Juan Pallais¹, Jeffrey Sparks², V. Michael Holers⁵, Undiagnosed Diseases Network¹, David Sweetser⁴, Joel Krier¹, Joseph Loscalzo¹, James Lederer¹ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School and Lausanne University Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵University of Colorado, Denver, CO
Background/Purpose: Few tools are available to evaluate the immune dysregulation in patients with severe autoimmune or inflammatory conditions that do not conform to well-defined rheumatologic…
Abstract Number: 0657 • ACR Convergence 2022
DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions
Xi Li, Yu Zhang, Bing Li and Haiqing Hua, Duality Biologics, Shanghai, China
Background/Purpose: BDCA2 (Blood Dendritic Cell Antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), a type I interferon-producing cells, which have been implicated in…
Abstract Number: 0742 • ACR Convergence 2022
Patient Factors Influencing Recruitment in a Telemedicine Randomized Clinical Trial
Lesley Jackson¹, Kiara Aaron¹, Jinoos Yazdany², Sarah Goglin³, Diana Perez⁴, David Chae⁵, Mary Margaretten², Faith Mugeta¹, Norma Techarukpong¹, Ellen McNeeley¹, Gary Cutter¹, kenneth saag¹ and Maria Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²UCSF, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴UCSF, Houston, TX, ⁵Tulane University School of Public Health and Tropical Medicine, New Orleans, LA
Background/Purpose: In the COVID era, telemedicine has assumed an increasing role in rheumatology care, yet questions remain about its comparative effectiveness and satisfaction relative to…
Abstract Number: 0795 • ACR Convergence 2022
Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications
Neel Thanavala¹, Kiho Son², Nardien Sedhom², Snehal Somalwar³, Zil Patel¹, Rameen Jamil², Carmen Venegas², Ashutosh Thakar², Agnes Yuen⁴, Melanie Kjarsgaard², Susan Waserman², Mylinh Duong², Parameswaran Nair², Christopher Carlsten⁴, Maggie Larche², Terence Ho², Sarah Svenningsen², KONSTANTINOS TSELIOS⁵ and Manali Mukherjee², ¹The Research Institute of St. Joe's Hamilton, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³The Research Institute of St Joe's Hamilton, Hamilton, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McMaster University, Population Health Research Institute, Hamilton, ON, Canada
Background/Purpose: Post-Acute Sequalae of COVID-19 (PASC), prevalent in ~20-30% of convalescent COVID-19 patients is characterized by new/persistent symptoms after the initial recovery. Certain autoantibodies have…
Abstract Number: 0990 • ACR Convergence 2022
KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study
RAMESH C. GUPTA¹, Paul Lunseth², Robert Levin³, Philip Waller⁴, Amber Khan⁵, Lester Hernandez⁵, Kai Wei⁶, Baisong Liao⁶, Tao Wang⁷, Kaiyue Hao⁷, Yanjiao Yin⁷ and Yong Guo⁷, ¹Shelby Research LLC, Memphis, TN, ²Clinical Research of West Florida, Tampa, FL, ³Clinical Research of West Florida. Inc., Clearwater, FL, ⁴Accurate Clinical Research, Houston, TX, ⁵Accurate Clinical Management, LLC., Houston, TX, ⁶Kangpu Biopharmaceuticals, Ltd., Shanghai, China, ⁷Kangpu Biopharmaceuticals, Ltd, Shanghai, China
Background/Purpose: KPG-818 is a novel CRL4-CRBN E3 ubiquitin ligase modulator that binds to CRBN with high affinity and leads to rapid and effective degradation of…
Abstract Number: 1212 • ACR Convergence 2022
Immunogenicity After Primary COVID-19 Vaccination in Patients with Immune-mediated Inflammatory Diseases: A Comparative Cohort Study
Kastriot Kastrati¹, Daniel Mrak², Peter Weber³, Lena Goethans³, Claudia Hana³, Elisabeth Simader², Thomas Hummel³, Eleonora Friedberg³, Daniel Aletaha⁴, Michael Bonelli² and Helga Radner², ¹Division of Rheumatology, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Vienna, Austria, ⁴Medical University Vienna, Wien, Austria
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) are at increased risk of severe COVID-19 disease courses. Real-world data on immunogenicity are scarce but crucial to…
Abstract Number: 1432 • ACR Convergence 2022
Pharmacokinetic Evaluation of a Proposed Adalimumab Biosimilar MSB11022 versus the US-Licensed Reference Product: Results of a Randomized, Double-Blind, 3-Arm Parallel-Group, Single-Dose Trial in Healthy Subjects
Anna Dryja¹, Anna Lucia Buccarello², Isabelle Gaillard² and Joëlle Monnet², ¹MTZ Clinical Research Sp. z o.o.,, Warsaw, Poland, ²Fresenius Kabi Swiss BioSim, Eysins, Switzerland
Background/Purpose: Adalimumab, a recombinant fully human monoclonal immunoglobulin G1 antibody, is a biologic directed against tumor necrosis factor-alpha indicated for use in a range of…
Abstract Number: 1696 • ACR Convergence 2022
Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus
Grace Hile, Feiyang Ma, Amanda Victory, Bin Xu, Mehrnaz Gharaee-Kermani, Elisabeth Pedersen, Rachael Wasikowski, Celine Berthier, Vladimir Ognenovski, Allison Billi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin disease in dermatomyositis (DM) is relapsing and often refractory to treatment, reflecting a lack of understanding of the mechanisms driving skin inflammation. DM…
Abstract Number: 1931 • ACR Convergence 2022
NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis
Esraa Eloseily¹, Alexander Valencia², Astha Malik², Rebekah Karns², Cyd Castro Rojas², Mosab Alquraish², Rebecca Marsh³, Alexei Grom⁴ and Alexander Miethke², ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Bone Marrow Transplantation & Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Mutations in the gene NOD2 encoding the nucleotide-binding oligomerization domain-containing protein 2 (NOD2) which controls innate responses to LPS have been linked to Blau…
Abstract Number: 2222 • ACR Convergence 2022
Lupus Clinical Flares in Patients with Gut Pathobiont Blooms Share a Novel Peripheral Blood Transcriptomic Immune Activation Profile
Gregg Silverman¹, Macintosh Cornwell¹, Peter Izmirly¹, Mala Masson¹, Jill Buyon¹, Doua Azzouz² and Kelly Ruggles¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Gross School of Medicine, New York, NY
Background/Purpose: SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common.…
Abstract Number: 0059 • ACR Convergence 2022
Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus
Kenneth Kalunian¹, Janice Ma², Konrad Pisarczyk², Richard Leff³, Kiruthi Palaniswamy⁴ and Li Long⁴, ¹University of California San Diego, La Jolla, CA, ²Maple Health Group, LLC, New York, NY, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…
Abstract Number: 0195 • ACR Convergence 2022
Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality
Jeffrey Curtis¹, Kimberly Garza², Cassie Clinton³, Heqin Yang², Alexicia Richardson², Cheryl Seals², Gary Hawkins², Chad Rose², William Benjamin Nowell⁴, Kelly Gavigan⁵ and Liana Fraenkel⁶, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Auburn University, Auburn, AL, ³University of Alabama at Birmingham, Hoover, AL, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Berkshire Medical Center, Lenox, MA
Background/Purpose: We aimed to assess enthusiasm for the use of virtual reality (VR) for clinical and educational use among people with rheumatologic diseases, comparing those…
Abstract Number: 0565 • ACR Convergence 2022
Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissues Using Single-cell Computational Omics
Juan Vargas¹, Nirmal Banda², Ian Mantel³, Anna Jonsson⁴, Kevin Wei⁵, Deepak Rao⁴, Susan Goodman⁶, Kevin D Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri⁴, Accelerating Medicines Partnership RA/SLE⁴, Michael Holers², Laura Donlin⁶ and Fan Zhang⁸, ¹School Public Health Biostatistics Department, Aurora, CO, ²Department of Medicine Division of Rheumatology, Aurora, CO, ³Weill Cornell Medicine, New York, NY, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁸University of Colorado, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune arthritis pathogenesis. In patients…
Abstract Number: 0662 • ACR Convergence 2022
Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The immunopathogenesis of cutaneous lupus erythematous (CLE) is highly diverse and involves activity of many different cell types and pathways. This heterogeneity is believed…
Abstract Number: 0743 • ACR Convergence 2022
Home-Based Telehealth in Rheumatology: A Systematic Review & Narrative Synthesis
Alexander Peck¹, Rebecca Grainger², Jeffrey Curtis³, John Cush⁴, Neelkamal Soares⁵, Nikhil Davuluri⁶, William Benjamin Nowell⁷, Sandeep Sodhi⁸, Danielle Grauer⁸, Natalie Fortune⁶, Shilpa Venkatachalam⁹, Daniel Kirby¹⁰, Jeffrey Alper¹¹, Kelly Gavigan¹², Laura Stradford⁷, David Curtis¹² and Swamy Venuturupalli¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Otago, Wellington, New Zealand, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴RheumNow, Dallas, TX, ⁵Western Michigan University, Kalamazoo, MI, ⁶Attune Health, Beverly HIlls, CA, ⁷Global Healthy Living Foundation, Nyack, NY, ⁸Illumination Health, Birmingham, AL, ⁹Global Healthy Living Foundation, New York, NY, ¹⁰Bendcare, Charlotte, NC, ¹¹Bendcare, Naples, ¹²Global Healthy Living Foundation, Upper Nyack, NY
Background/Purpose: Home based telehealth (HBT) visits, where a patient is located at home with a remote provider, became common during the COVID-19 pandemic. Patients now…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].